ClinicalTrials.gg
Not yet recruitingNCT07944963Updated Nov 18, 2026

Sacral Erector Spinae Plane Block for Catheter-Related Bladder Discomfort After HoLEP

An interventional study of Ultrasound-guided bilateral sacral erector spinae plane block and Standard General Anesthesia in Catheter-Related Bladder Discomfort, Benign Prostatic Hyperplasia and Urinary Catheterization, sponsored by Ankara Etlik City Hospital. Not yet recruiting at 1 site in Turkey (Türkiye). Open to male participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Ankara Etlik City Hospital · Not applicable, Interventional, and Prevention

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 40 studies in Prostatic Hyperplasia with a site in Turkey — 15 open to participants now, 16 under way, none of them phase 3. Prostatic Hyperplasia · Turkey.

Planned enrollment
8th of 20
100 · median 88
Started
2026
with 11 others
No phase
14 of 40
7 open now
Primary completion
2027-03
later than 5 of 15 live
Registered
40th of 40
by date

Among the 40 studies in Prostatic Hyperplasia with a site in Turkey, this one is the 8th largest by planned enrollment of the 20 interventional ones that give a count, is one of 12 that started in 2026, is one of 14 with no phase, reaches primary completion later than 5 of the 15 other live ones, and was the 40th registered.

Prostatic Hyperplasia

830 studies on the registry are indexed under Prostatic Hyperplasia; 180 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

15 of the 40 studies in Prostatic Hyperplasia with a site in Turkey are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 50 Years to 80 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Prostatic Hyperplasia with a site in Turkey, or all of them as a file.
02

Study summary

Catheter-related bladder discomfort (CRBD) is common after holmium laser enucleation of the prostate (HoLEP). This single-center, randomized, controlled, assessor-blinded trial evaluates whether an ultrasound-guided bilateral sacral erector spinae plane (S-ESP) block performed before general anesthesia reduces the incidence of CRBD compared with general anesthesia alone in men aged 50 to 80 years undergoing elective HoLEP. The primary outcome is the incidence of CRBD at 1 hour after surgery.

Read the detailed description

Catheter-related bladder discomfort (CRBD) is a common and distressing postoperative symptom complex in male patients undergoing Holmium Laser Enucleation of the Prostate (HoLEP), characterized by a suprapubic burning sensation, an urge to void, and involuntary bladder spasms due to three-way urinary catheterization and continuous bladder irrigation. The sacral erector spinae plane (S-ESP) block is an ultrasound-guided interfascial plane block that targets the S2-S4 sacral nerve roots, which provide both somatic (via the pudendal nerve) and visceral parasympathetic (via pelvic splanchnic nerves) innervation to the lower urinary tract. While current evidence regarding the efficacy of the S-ESP block against a no-block control group in HoLEP surgery is limited, blocking these sacral pathways may effectively modulate afferent bladder stimuli.

A total of 100 male patients aged 50 to 80 years with ASA physical status I-III scheduled for elective HoLEP surgery under general anesthesia will be randomly assigned in a 1:1 ratio to either the S-ESP block group (Group S, n=50) or the standard care control group (Group G, n=50) using computer-generated randomization and sealed opaque envelopes.

Patients in Group S will be placed in the prone position approximately 30 minutes before surgery under standard monitoring. Using a convex ultrasound transducer (GE HealthCare C1-5 probe) in a longitudinal paramedian orientation at the S2 intermediate sacral crest level, a 22G 80-100 mm echogenic block needle will be advanced in-plane in a craniocaudal direction into the fascial plane between the erector spinae aponeurosis and the sacral crest. Following hydrodissection with 1-2 mL normal saline and negative aspiration, 20 mL of 0.25% bupivacaine will be injected on each side (total 40 mL, 100 mg; not exceeding the maximum safe dose of 2 mg/kg). Sensory blockade will be assessed 30 minutes after block completion via pinprick testing over the bilateral S2-S4 dermatomes.

Both groups will receive a standardized general anesthesia protocol: induction with IV fentanyl (1 mcg/kg), propofol (2-2.5 mg/kg), and rocuronium (0.3 mg/kg) to facilitate laryngeal mask airway (LMA) insertion, followed by maintenance with 1 MAC sevoflurane and titrated remifentanil infusion (0.05-0.2 mcg/kg/min). Approximately 30 minutes before the end of surgery, all patients will receive IV paracetamol (1 g) and IV tramadol (100 mg) for multimodal analgesia, followed by routine postoperative IV paracetamol (1 g twice daily).

An independent anesthesiologist blinded to group allocation will assess postoperative outcomes at 30 minutes and at 1, 2, 4, 6, 12, and 24 hours. If the Visual Analog Scale (VAS) pain score is ≥4, IV tramadol (1 mg/kg, up to 400 mg/day) will be administered as rescue analgesia. If the CRBD score is ≥2 after excluding mechanical catheter obstruction, rescue antispasmodic or antimuscarinic medication will be administered. Quality of recovery will be evaluated at 24 hours using the validated Turkish version of the 15-item Quality of Recovery scale (QoR-15T).

03

Conditions studied

  • Catheter-Related Bladder Discomfort
  • Benign Prostatic Hyperplasia
  • Urinary Catheterization
  • Pain, Postoperative

Keywords

  • sacral erector spinae plane block
  • holmium laser enucleation of the prostate
  • catheter-related bladder discomfort
  • regional anesthesia
  • quality of recovery
  • HoLEP
  • QoR-15
  • Postoperative pain
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male patients aged between 50 and 80 years
  • (ASA) physical status class I to III
  • Scheduled for elective Holmium Laser Enucleation of the Prostate (HoLEP) surgery under general anesthesia
  • Patients who agree to participate in the study and sign the written form

Exclusion criteria

Exclusion Criteria:

  • Age under 50 years or over 80 years
  • class IV or higher
  • Known or allergy to local anesthetics
  • History of chronic opioid use
  • Chronic pain syndrome
  • History of peripheral neuropathy, sacral neurological disease, or neurogenic bladder
  • Overactive bladder or prominent preoperative bladder irritation symptoms
  • History of previous prostate, bladder neck, or lower urinary tract surgery
  • Active urinary tract infection
  • Anticoagulant/antiplatelet use that contraindicates block administration according to current regional anesthesia guidelines, or coagulopathy
  • Infection or severe dermatological lesion at the block application site
  • Severe renal failure ( \< 30 mL/min/1.73m2) or clinically significant hepatic failure
  • Cognitive impairment, communication difficulty, or psychiatric/neurological condition preventing postoperative assessments
  • Anticipated need for postoperative intensive care unit admission
  • Presence of a preoperative indwelling urinary catheter
  • Emergency surgery
  • Patient refusal or withdrawal of consent
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    S-ESPB Group

    Ultrasound-guided bilateral sacral erector spinae plane block with 20 mL of 0.25% bupivacaine per side, performed about 30 minutes before surgery, followed by standardized general anesthesia.

    Procedure: Ultrasound-guided bilateral sacral erector spinae plane block

  • Active comparator
    Standard Care Group

    Standardized general anesthesia without any block or sham injection.

    Other: Standard General Anesthesia

Interventions

  • ProcedureUltrasound-guided bilateral sacral erector spinae plane block

    Ultrasound-guided bilateral sacral erector spinae plane block with 20 mL of 0.25% bupivacaine per side, performed about 30 minutes before surgery, followed by standardized general anesthesia

  • OtherStandard General Anesthesia

    Standardized general anesthesia without any block.

06

What researchers measure

Primary outcomes

  1. Incidence of Catheter-Related Bladder Discomfort (CRBD) at Postoperative 1 Hour

    CRBD is graded on a 4-point scale: 0 = none; 1 = mild (reported only on questioning); 2 = moderate (reported spontaneously, without behavioral responses); 3 = severe (reported spontaneously with behavioral responses such as strong verbal response, flailing limbs or attempts to remove the catheter). Incidence is the proportion of patients with a score of 1 or higher.

    Time frame: 1 hour after surgery

Secondary outcomes

  1. Incidence of CRBD at other time points

    Proportion of patients with CRBD score of 1 or higher

    Time frame: 30 minutes and 2, 4, 6, 12 and 24 hours after surgery

  2. Severity of CRBD

    CRBD severity will be graded on a 4-point ordinal scale from 0 (none) to 3 (severe). Moderate-to-severe CRBD is defined as a score ≥2.

    Time frame: 30 minutes and 1, 2, 4, 6, 12 and 24 hours after surgery

  3. Postoperative pain score

    Postoperative pain intensity will be assessed using a 10-cm Visual Analog Scale (VAS) ranging from 0 (no pain) to 10 (worst pain).

    Time frame: 30 minutes and 1, 2, 4, 6, 12 and 24 hours after surgery

  4. Intraoperative remifentanil consumption

    Total amount of intraoperative remifentanil consumed, recorded in micrograms (mcg) and normalized to body weight and duration (mcg/kg/hour).

    Time frame: Intraoperative period

  5. Total Postoperative Rescue Analgesic Consumption

    Total intravenous tramadol dose in milligrams

    Time frame: First 24 hours after surgery

  6. Time to First Rescue Analgesic Request

    Minutes from end of surgery to first rescue tramadol dose

    Time frame: First 24 hours after surgery

  7. Antispasmodic or antimuscarinic requirement

    Proportion of patients requiring additional antispasmodic or antimuscarinic medication for persistent moderate-to-severe CRBD (score ≥2)

    Time frame: First 24 hours after surgery

  8. Incidence of Postoperative Nausea and Vomiting (PONV) and Other Adverse Events

    Number and percentage of participants experiencing postoperative nausea and vomiting (PONV) or any block- or anesthesia-related adverse events.

    Time frame: First 24 hours after surgery

  9. Postoperative Quality of Recovery Score (QoR-15T)

    Quality of recovery will be evaluated using the validated Turkish version of the 15-item Quality of Recovery scale (QoR-15T). Total scores range from 0 to 150, with higher scores indicating better postoperative recovery quality.

    Time frame: At 24 hours after surgery

07

Study locations

1 site
08

References and documents

Publications

  • Dost B, Narayanan M, Marrone F, De Cassai A, Tulgar S, Aksu C, Merjavy P, Chin KJ. The Sacral Erector Spinae Plane Block: A Narrative Review. Pain Ther. 2026 Feb;15(1):131-147. doi: 10.1007/s40122-025-00807-6. Epub 2025 Dec 23. PubMed 41432969 ↗
  • Rinaldi P, Garo ML. Efficacy and safety of sacral erector spinae plane (S-ESP) block in adult and pediatric patients during surgical procedures: A comprehensive systematic review and meta-analysis. J Clin Anesth. 2026 Apr;111:112181. doi: 10.1016/j.jclinane.2026.112181. Epub 2026 Mar 11. PubMed 41819624 ↗
  • Akkaya T, Ozkan D, Karakoyunlu N, Ergil J, Gumus H, Ersoy H, Comert A, Acar HI, Yildiz S. Pudendal block in transurethral prostatectomy: A randomised trial. Eur J Anaesthesiol. 2015 Sep;32(9):656-7. doi: 10.1097/EJA.0000000000000172. No abstract available. PubMed 25387302 ↗
  • Olgun Keles B, Tekir Yilmaz E, Altinbas A. Comparison between the Efficacy of Sacral Erector Spina Plane Block and Pudendal Block on Catheter-Related Bladder Discomfort: A Prospective Randomized Study. J Clin Med. 2024 Jun 20;13(12):3617. doi: 10.3390/jcm13123617. PubMed 38930146 ↗
  • Wang SY, Qiu Q, Shen X. Effect of Pudendal Nerve Block on the Prevention of Postoperative Bladder Spasm and Catheter-Related Bladder Discomfort in Male Patients Undergoing Transurethral Holmium Laser Enucleation of the Prostate. Clin Interv Aging. 2022 Nov 30;17:1729-1738. doi: 10.2147/CIA.S384612. eCollection 2022. PubMed 36474581 ↗

Individual participant data

Plan to share: No — All personal data will be anonymized and individual participant data will not be made publicly available in accordance with institutional ethics committee approval.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Mar 2027, 3 months later.

Of 153 non-industry interventional studies with no phase under Prostatic Hyperplasia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 48. This study's planned 3 months is below that.

Counting every sponsor, half of 205 studies reached it within 26 months; a quarter within 15 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartEst.
Nov 19, 2026
Primary completionEst.
Mar 16, 2027
CompletionEst.
Mar 31, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944963
Responsible party
Kadriye Dıvrak (Resident Physician, Ankara Etlik City Hospital) — Principal investigator
First posted
Nov 18, 2026
Start date
Nov 19, 2026 (estimated)
Primary completion
Mar 16, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Kadriye Divrak, MD
Contact
kadriyedivrak@gmail.com
00905453712155
Derya Ozkan, Prof., MD
Contact
derya_z@yahoo.com
00905425843638
Derya Ozkan, Prof., MD
study director · Ankara Etlik City Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion